이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NeoGenomics 관리

관리 기준 확인 2/4

NeoGenomics' CEO는 Chris Smith, Aug2022 에 임명되었습니다 의 임기는 1.83 년입니다. 총 연간 보상은 $ 11.67M, 8.6% 로 구성됩니다. 8.6% 급여 및 91.4% 보너스(회사 주식 및 옵션 포함). 는 $ 8.84M 가치에 해당하는 회사 주식의 0.53% 직접 소유합니다. 8.84M. 경영진과 이사회의 평균 재임 기간은 각각 1.7 년과 3.4 년입니다.

주요 정보

Chris Smith

최고 경영자

US$11.7m

총 보상

CEO 급여 비율	8.6%
CEO 임기	1.9yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	3.5yrs

최근 관리 업데이트

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07

NeoGenomics: Gambling On Growth

Dec 16

NeoGenomics: Profitability Headwinds Compress Valuation, Shares

Sep 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Sep 24

NeoGenomics: Strong Growth Potential For A Leader In Cancer Diagnostic Testing

Jul 02

NeoGenomics completes Inivata acquisition

Jun 18

CEO 보상 분석

Chris Smith 의 보수는 NeoGenomics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$84m
Dec 31 2023	US$12m	US$1m	-US$88m
Sep 30 2023	n/a	n/a	-US$96m
Jun 30 2023	n/a	n/a	-US$115m
Mar 31 2023	n/a	n/a	-US$126m
Dec 31 2022	US$15m	US$346k	-US$144m

보상 대 시장: Chris 의 총 보상 ($USD 11.67M )은 US 시장( $USD 5.67M ).

보상과 수익: Chris 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Chris Smith (61 yo)

1.9yrs

테뉴어

US$11,665,946

보상

Mr. Christopher Michael Smith, also known as Chris, serves as Chief Executive Officer at NeoGenomics Laboratories, Inc. since August 2022. He serves as Director at NeoGenomics Laboratories, Inc. since 2023...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christopher Smith	CEO & Director	1.9yrs	US$11.67m	0.53% $ 9.5m
Jeffrey Sherman	Chief Financial Officer	1.6yrs	US$3.55m	0.12% $ 2.1m
Vishal Sikri	President of Advanced Diagnostics	2.5yrs	US$2.37m	0.10% $ 1.8m
Melody Harris	President & COO of Informatics	1.6yrs	US$4.69m	0.085% $ 1.5m
Warren Stone	Chief Commercial Officer	1.7yrs	US$3.01m	0.079% $ 1.4m
Gregory Aunan	Chief Accounting Officer	1.2yrs	데이터 없음	0.011% $ 201.4k
Kendra Sweeney	Vice President of Investor Relations & Communications	no data	데이터 없음	데이터 없음
Alicia Olivo	Executive VP of Business Development	2.3yrs	데이터 없음	0.035% $ 625.0k
Hutan Hashemi	Chief Compliance Officer	2.3yrs	데이터 없음	데이터 없음
Derek Lyle	Chief Medical Officer	3.5yrs	데이터 없음	데이터 없음
Gary Passman	Chief Culture Officer	1.5yrs	데이터 없음	데이터 없음
Fernando López-Díaz	Director of Clinical Science	no data	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: NEO 의 관리팀은 경험 (평균 재직 기간 1.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christopher Smith	CEO & Director	1.9yrs	US$11.67m	0.53% $ 9.5m
Michael Kelly	Independent Director	4yrs	US$317.50k	0.016% $ 284.5k
Lynn Tetrault	Independent Chair of the Board	9.1yrs	US$365.00k	0.039% $ 697.4k
Bernard Fox	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Riccardo Dalla-Favera	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Anthony Zook	Independent Director	1.1yrs	US$276.23k	데이터 없음
Steven Rosen	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
James Downing	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Stephen Kanovsky	Independent Director	7yrs	US$309.20k	0.019% $ 344.8k
Razelle Kurzrock	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Alison Hannah	Member of Scientific Advisory Board & Independent Director	9.1yrs	US$305.00k	0.084% $ 1.5m
Mark Rubin	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: NEO 의 이사회는 경험(평균 재직 기간 3.4 년)으로 간주됩니다.

NeoGenomics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

NeoGenomics, Inc. Announces Executive Changes

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

Recent updates

NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Price target increased by 7.2% to US$21.55

Full year 2023 earnings: EPS exceeds analyst expectations

NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024

NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

NeoGenomics Laboratories, Inc. to Appeal Ruling

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Consensus estimates of losses per share improve by 11%

NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neogenomics, Inc. Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

NeoGenomics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

NeoGenomics, Inc.'s RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics, Inc. and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics, Inc. to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

Price target increased by 7.7% to US$21.64

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.40 loss in 1Q 2022)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics, Inc. Announces Results of a New Study of the RaDaR Assay in Patients with Muscle-Invasive Bladder Cancer

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

The Klein Law Firm Announces Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Neogenomics, Inc. Shareholders

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Gibbs Law Group Announces Files Class Action Lawsuit Against NeoGenomics Inc

NeoGenomics, Inc. Announces Executive Changes

Neogenomics, Inc. Announces Radar Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics Appoints David Perez to its Board of Directors

NeoGenomics, Inc. Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

NeoGenomics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NeoGenomics: Market Punishment Continues, But Looks Justified

NeoGenomics grants CEO restricted shares, stock options

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

NeoGenomics, Inc. Appoints Chris Smith as Chief Executive Officer, Effective August 15, 2022

NeoGenomics gets new CEO

Price target decreased to US$17.75

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

NeoGenomics, Inc.(NasdaqCM:NEO) dropped from Russell 2000 Growth-Defensive Index

NeoGenomics, Inc. Announces Resignation of Douglas Brown as Chief Strategy and Corporate Development Officer

Neogenomics, Inc. Announces Executive Changes, Effective May 23, 2022

Consensus EPS estimates fall by 21%

President & COO of Lab Operations notifies of intention to sell stock

Price target decreased to US$19.45

First quarter 2022 earnings: EPS misses analyst expectations

High number of new and inexperienced directors

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

NeoGenomics, Inc., Annual General Meeting, Jun 02, 2022

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

NeoGenomics, Inc. Provides Revenue Guidance for the First Quarter 2022

NeoGenomics, Inc. Announces Management Changes

Chief Financial Officer notifies of intention to sell stock

Price target decreased to US$30.20

Full year 2021 earnings: EPS exceeds analyst expectations